Introduction
Linoleic acid (LA) and arachidonic acid (AA) are the major n-6 polyunsaturated fatty acids (PUFAs) in the diet. 1 While LA is an essential fatty acid (FA) and thus entirely dependent on dietary intake, AA can in addition be obtained by endogenous metabolism of LA. LA is mainly found in nuts and vegetable oils and AA in eggs, poultry and meat. 2 3 Reports from other patient populations suggest that LA may prevent development of type 2 diabetes mellitus (T2DM) 4 possibly through beneficial effects on insulin sensitivity. 5 The mechanism is not completely revealed but the anti-inflammatory properties of LA is likely involved. In contrast, AA and its metabolites also have pro-inflammatory and pro-glycemic effects 6 , and both hyperglycemia and inflammation are independent risk factors for cardiovascular (CV) disease, which is the leading cause of death in renal transplantation recipients (RTRs). 7 To our knowledge, no data exist on the long-term impact of n-6 PUFA consumption in patients undergoing organ transplantation and no previous study has assessed associations between plasma n-6 PUFA levels and inflammatory or CV risk markers in a renal transplant cohort.
The aim of the present study was to assess whether plasma levels of LA and AA were associated with mortality and graft loss in RTRs. In addition, we assessed cross-sectional associations between plasma LA and AA levels and various inflammatory and CV risk markers.
Materials and methods

Study population and clinical data
The study population and design have previously been described in detail. [8] [9] [10] In short, 1988 out of 2345 eligible renal transplant recipients, transplanted at Oslo University Hospital, Rikshospitalet, during September 1999 through October 2011, were included in the study. Patients not eligible for participation in the study included patients under the age of 16 years, patients transferred to their local hospitals within 10 weeks after transplantation, and patients who suffered graft failure or died within the first 10 weeks following renal transplantation. The immunosuppressive protocol was based on a combination of a calcineurin inhibitor, prednisolone and a cell proliferation inhibitor, with some variation during the study period. Until 2007, the calcineurin inhibitor of choice was cyclosporine, followed by a period where the choice of calcineurin inhibitor (tacrolimus or cyclosporine) was based on recipient age and CV risk profile. Tacrolimus has been the calcineurin inhibitor of choice from 2012, but patients started on cyclosporine were not switched to tacrolimus. Statin became standard therapy during the study period, with a coverage from 30% in 2000 to >70% from 2007 and onwards.
The study was approved by the Regional Committees for Medical and Health Research Ethics in Norway and was performed in accordance with the Declaration of Helsinki.
Data collection and laboratory methods
Clinical data were obtained from medical records. The Norwegian Renal Registry, which includes all Norwegian patients on renal replacement therapy, provided endpoint data. Overall renal graft loss included both functional grafts lost due to recipient death and death censored graft loss (return to dialysis therapy or renal re-transplantation). At 10 weeks post-transplant, all patients underwent a uniform clinical investigation at the Laboratory for renal physiology at Oslo University Hospital, Rikshospitalet. Blood was sampled and aliquots of biobanked samples were sent to The Lipid Research Center, Aalborg University Hospital for FA analysis by gas chromatography as previously described. 8 Individual FAs were identified and quantified as weight percentage (wt%) of total plasma FA. Plasma inflammation markers were analyzed at The Research Institute of Internal Medicine at Oslo University Hospital, Rikshospitalet and at The Research Laboratory, Nordland Hospital, Bodø using enzyme immunoassay and multiplex cytokines assay as appropriate. 9 In nondiabetic patients, fasting plasma glucose (fPG) was measured and 2-hours post-challenge plasma glucose (2hPG) was obtained during a standard OGTT. Inflammatory markers were measured in patients transplanted from 2007. Other parameters were measured from 1999.
Statistics
The main statistical approach was survival analysis, using Cox proportional hazard regression with all-cause mortality and overall graft loss as outcomes, and proportional hazard regression model for the subdistribution of competing risks as described by Fine and Grey 11 for outcomes CV mortality and death censored graft loss. We estimated crude, age and gender adjusted and multivariable adjusted hazard ratios (HR) of reaching mortality and graft loss end-points. Proportional hazard assumptions were checked by inspection of the log-log survival time plots and by a formal hypothesis test (Schoenfeld residuals). Crosssectional associations between plasma phospholipid levels of LA and AA and inflammatory biomarkers and CV risk markers at 10 weeks post-transplant were assessed by age and gender adjusted and multivariable adjusted linear regression. Candidate variables were included in final regression models in a stepwise forward manner (inclusion criteria of p<0.10). Plasma levels of either LA or AA were forced into the final model. Statins were paused during the first 3 months after renal transplantation and thus do not influence cross-sectional associations. Only patients without overt DM underwent measurements of fPG and 2hPG. Associations between plasma phospholipid LA and AA levels and various inflammatory and CV risk markers are presented as unstandardized regression coefficient (Unstd. β-coeff.), corresponding 95% confidence intervals (CI) and standardized regression coefficient (Std. β-coeff.). Due to non-normal distribution, dialysis vintage and inflammatory biomarkers were logarithmically transformed before they were entered as variables in linear regression analyses. Thus, for inflammatory biomarkers, the presented Unstd. β-coeff. and corresponding 95% CI represents the anti-logarithm of obtained results. SPSS ® version 24.0 (IBM, NY, US) and STATA ® version 14.0 (Stata Corp, College Station, Texas, US) were used for the statistical analysis. A two-sided p-value of < 0.05 was considered statistically significant.
Results
Demographics
Levels of AA and LA in plasma were inversely correlated (Pearsons'r = -0.30). As can be seen in Table 1 , multiple baseline characteristics were associated with AA and LA levels. In particular, patients with high LA and AA were younger, male, had better renal function, used different immunosuppressive agents, had a higher prevalence of DM at the time of transplantation and a different biochemical profile including lower total cholesterol. Patients with high LA had lower body mass index (BMI) while patients with high AA had higher BMI.
During follow-up (19 906 person-years with a median follow-up of 9.6 years) there were 595 deaths (30%), including 225 deaths from cardiovascular causes. A total of 805 renal grafts were lost, either due to recipient death (n=497) or death censored graft loss (n=308).
Linoleic acid
In univariate analysis, we found significant inverse associations between plasma LA levels and overall graft loss and all-cause and CV mortality, but not death censored graft loss (Table 2) . After adjustment for traditional and transplant specific risk factors, no significant associations were found between plasma LA levels and mortality or graft loss end-points (Table 2 ). Subgroup analyses revealed no interactions between LA levels and DM or indices of glucose metabolism on long-term outcomes.
In a multivariable linear regression analysis, plasma levels of LA were inversely associated with fPG and 2hPG and positively associated with plasma high-density lipoprotein (HDL) cholesterol levels (Table 3) . Plasma LA levels were negatively associated with levels of growth differential factor 15 (GDF-15) and chemerin (Table 4) . Multivariable linear regression revealed that plasma AA was negatively associated with plasma HDL cholesterol levels and positively associated with fPG and 2hPG (Table 3) . Further, regression analysis showed positive associations between plasma AA level and GDF-15 and chemerin (Table 4) .
Arachidonic acid
Discussion
Plasma levels of LA and AA levels were not associated with either patient or graft survival after adjustment for confounders. We found negative associations between plasma LA levels and pro-glycemic and proinflammatory indices, while positive associations with the same markers were found for plasma AA levels.
Patient and graft survival
High levels of LA and AA were often found in young RTRs, which inevitably will infer confounding, and crude survival data should be interpreted with caution. After adjustment for multiple confounders, we found no significant associations between plasma levels of LA or AA, mortality and graft loss, suggesting no survival benefit from enriching the diet with LA, despite possible beneficial anti-glycemic and antiinflammatory effects. Much of the concern regarding n-6 PUFA consumption is related to unfavorable metabolic and inflammatory effects of eicosanoid deriving from AA. The findings of this study do not support this concern, as no unfavorable association with long-term outcomes was found in patients with high plasma levels of AA.
Inflammation, lipid and glucose metabolism
We found that higher plasma levels of LA are associated with lower fPG and 2hPG, even after adjustment for potential confounders. A similar cross-sectional correlation between plasma LA and glucose levels were found in a recent population-based study from the Netherlands. 12 In the present study, plasma LA levels showed a particularly strong negative association with chemerin, a cytokine involved in adipocyte differentiation, glucose and lipid metabolism and immune regulation. 13 14 Chemerin levels normalize early after renal transplantation and do not reflect pre-transplant levels at 10 weeks post-transplant. 15 Since both pre-and post-transplantation DM is frequent and associated with increased mortality, 16 the potential antiglycemic properties of LA would be of particular interest in an organ transplant cohort.
In humans, LA has been shown to lower low-density lipoprotein (LDL) cholesterol, and higher PUFA levels are associated with a reduced ratio of total to HDL cholesterol. 17 Reports from cohort studies in the general population indicate that LA consumption lower the risk of CV disease. 18 19 We found a positive association between plasma LA levels and HDL cholesterol levels in this cohort, but no association with LDL cholesterol.
Higher plasma LA levels were also associated with lower GDF-15 levels, a transforming growth factor-beta superfamily stress-response cytokine, associated with DM, cancer, CV disease and mortality. 20 In humans, short-term high dose LA consumption reduced circulating pro-inflammatory cytokine levels. 21 However, we did not detect an association between plasma LA levels and markers of tumor necrosis factor pathway activation. For AA, there is firm evidence for a pro-inflammatory effect, 6 and we found a positive association with GDF-15 levels.
We have previously reported that higher plasma levels of LA were associated with improved renal graft function during the first year after transplantation. 22 However, we did not find an association between plasma LA levels and death censored graft loss in this cohort.
Strengths and limitations
In addition to the observational design, there are several limitations in the present study. We lack data on dietary habits to adjust for the full matrix of nutrients. There might be residual confounding from a potentially healthier lifestyle associated with higher levels of LA. Plasma FA composition at 10 weeks posttransplant may not reflect long-term FA profile and this concern extends to plasma inflammatory biomarkers and CV risk markers, also analyzed at the same point of time. Circulating inflammatory cytokines may stem from sources outside the renal graft and we lack data on urinary inflammation markers to check for consistency. Our findings may not apply to other patient populations with different dietary habits. This study also has substantial strengths, including a large and well-defined population, uniform clinical procedures, a long follow-up period, few missing data and adjustment for several traditional and transplant-specific mortality and graft loss risk factors.
Conclusion
In this renal transplant cohort, we found no associations between plasma levels of LA and survival. Plasma LA levels were negatively associated with fPG, 2hPG and chemerin, while plasma AA level showed positive associations with these glycemic indices, suggesting an anti-glycemic effect of LA consumption and a pro-glycemic effect of AA consumption. Inverse associations with GDF-15 signals that LA might possess anti-inflammatory effects. Estimated relative risk of reaching all-cause mortality and overall graft loss end-points according to linoleic acid levels using multivariate Cox proportional hazard regression and relative risk of reaching death censored graft loss and cardiovascular mortality end-points using multivariable subdistributional hazard regression adjusting for the competing risks of recipient death (death censored graft loss) or death from noncardiovascular causes (cardiovascular mortality).
Candidate variables in multivariable survival analysis registered at time of transplantation: Recipient age and gender, donor age, transplant era (date of transplantation prior to or after 1 st January 2007), atherosclerotic disease (coronary artery, cerebrovascular and/or peripheral vascular disease), diabetes mellitus, smoking status (current smoker, former smoker or life-long non-smoker), dialysis vintage (time in dialysis prior to kidney transplantation), preemptive transplantation (no dialysis therapy before kidney transplantation), first or previous renal transplant, donor status (living or deceased) and number of human leukocyte antigen DR mismatches. Candidate variables registered at 10 weeks post-transplant: Choice of calcineurin inhibitor, body mass index, plasma cholesterol, serum albumin, estimated glomerular filtration rate and use of antihypertensive drugs. 
